EGFR and neoplasm: As mentioned above, bi-specific antibodies designed to bind 4-1BB and a tumor antigen simultaneously, such as Her2, EGFR, or CEACAM5, should result in the selective activation of 4-1BB pathways in the TME (43, 81).